Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Exploration of new strategies for the prevention of breast cancer metastasis is justifiably at the center of clinical attention. In this study, we combined a computational biology approach with mechanism-based preclinical trials to identify inhibitors of activin-like receptor kinase (ALK) 1 as effective agents for blocking angiogenesis and metastasis in breast cancer. Pharmacologic targeting of ALK1 provided long-term therapeutic benefit in mouse models of mammary carcinoma, accompanied by strikingly reduced metastatic colonization as a monotherapy or part of combinations with chemotherapy. Gene-expression analysis of breast cancer specimens from a population-based nested case-control study encompassing 768 subjects defined endothelial expression of ALK1 as an independent and highly specific prognostic factor for metastatic manifestation, a finding that was corroborated in an independent clinical cohort. Overall, our results suggest that pharmacologic inhibition of endothelial ALK1 constitutes a tractable strategy for interfering with metastatic dissemination of breast cancer.

[1]  D. Nielsen,et al.  A systematic review of bevacizumab efficacy in breast cancer. , 2014, Cancer treatment reviews.

[2]  G. Hortobagyi,et al.  Past, present, and future challenges in breast cancer treatment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Mariani,et al.  PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial , 2014, Investigational New Drugs.

[4]  K. Czene,et al.  Abstract P6-06-17: Gene signature model predicts metastatic onset better than standard clinical markers – Nested case-control design uniquely enables enrichment for biologically relevant features , 2013 .

[5]  Suzanne F. Jones,et al.  Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer , 2013, Clinical Cancer Research.

[6]  B Rachet,et al.  Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study , 2013, British Journal of Cancer.

[7]  M. Goumans,et al.  Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination , 2013, The Journal of experimental medicine.

[8]  K. Gelmon,et al.  Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. , 2012, Cancer treatment reviews.

[9]  A. Aguzzi,et al.  Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. , 2012, Cancer cell.

[10]  R. Johnson,et al.  Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success , 2012, Cancer cell.

[11]  K. Pietras,et al.  ALK1 as an emerging target for antiangiogenic therapy of cancer. , 2011, Blood.

[12]  R. Simon,et al.  Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. , 2011, Cancer research.

[13]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[14]  N. Solban,et al.  ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth , 2010, Molecular Cancer Therapeutics.

[15]  M. Goumans,et al.  Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis , 2010, The Journal of experimental medicine.

[16]  B. Schaffhausen,et al.  Lessons in Signaling and Tumorigenesis from Polyomavirus Middle T Antigen , 2009, Microbiology and Molecular Biology Reviews.

[17]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[18]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[19]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[20]  J. Massagué,et al.  Molecular basis of metastasis. , 2008, The New England journal of medicine.

[21]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[22]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[23]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[24]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  R. Schulick,et al.  Endocrine tumors of the pancreas , 2006, Current opinion in oncology.

[26]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[27]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[28]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[29]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[30]  G. Sledge,et al.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. , 2001, Cancer research.

[31]  N. Weidner,et al.  Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow , 1998, The Journal of pathology.

[32]  A. Moustakas,et al.  Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer , 2007 .